EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Glucocorticoid Treatment in Community-Acquired Pneumonia

Pierre-François Dequin, Marco Confalonieri

Seminars in Respiratory and Critical Care Medicine · 01.02.2026 · 47 (01) · 066-076

DOI: 10.1055/a-2704-6851 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Respiratory and Critical Care Medicine, erschienen am 01.02.2026. Verfasst von Pierre-François Dequin und 1 weiteren Autor:innen. Beteiligte Einrichtung: Inserm UMR 1100 Centre d'Etudes des Pathologies Respiratoires, Université de Tours, Tours, France. Hauptthemen laut MEDLINE: Community-Acquired Infections, Glucocorticoids, COVID-19 Drug Treatment, Pneumonia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: French Ministry of Health, Aerogen and Fisher and Paykel, Aridis Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite a fairly large number of comparative trials (which are, however, very heterogeneous), the role of corticosteroids in the adjuvant treatment of community-acquired pneumonia remains controversial. Nevertheless, recent randomized trials with adequate power in intensive care unit patients, albeit with conflicting results, have contributed to clarifying our understanding of this issue. More accurate phenotyping of patients likely to benefit from corticosteroid treatment must now be performed. In COVID-19 pneumonia, their benefit is not in question. For certain specific pathogens, including viral pathogens, their indications must be refined. They are still not recommended for influenza. They appear generally safe for short-term use in select populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Community-Acquired InfectionsGlucocorticoidsCOVID-19 Drug TreatmentPneumoniaHumansCOVID-19SARS-CoV-2Intensive Care UnitsRandomized Controlled Trials as TopicCommunity-Acquired Pneumonia

Substanzen

Glucocorticoids

Autor:innen und Institutionen

  • Inserm UMR 1100 Centre d'Etudes des Pathologies Respiratoires, Université de Tours, Tours, France.
  • Service de Médecine Intensive, Réanimation et Centre d'Investigation Clinique INSERM CIC 1415, Hôpital Bretonneau, CHU de Tours, Tours, France.
  • CRICS-TriGGERSep F-CRIN Network.
  • Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
  • Pulmonology Unit, University Hospital of Cattinara, Trieste, Italy.

Förderung

  • French Ministry of Health
  • Aerogen and Fisher and Paykel
  • Aridis Pharmaceutical
  • AOP Health

Zitieren

APA

Dequin, P. F., & Confalonieri, M. (2026). Glucocorticoid Treatment in Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 47(01), 066-076. https://doi.org/10.1055/a-2704-6851

Vancouver

Dequin PF, Confalonieri M. Glucocorticoid Treatment in Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine. 2026;47(01):066-076. doi:10.1055/a-2704-6851

BibTeX
@article{Dequin2026,
  author = {Dequin, Pierre-François and Confalonieri, Marco},
  title = {Glucocorticoid Treatment in Community-Acquired Pneumonia},
  journal = {Seminars in Respiratory and Critical Care Medicine},
  year = {2026},
  volume = {47},
  number = {01},
  pages = {066--076},
  doi = {10.1055/a-2704-6851}
}
Kostenlos starten →